These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26824527)

  • 1. Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia.
    Choi JD; Kim JH; Ahn SH
    Urol Int; 2016; 96(4):406-12. PubMed ID: 26824527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
    Lin VC; Liao CH; Wang CC; Kuo HC
    J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
    Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
    Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cutoff value of transitional zone index predicting the efficacy of dutasteride on subjective symptoms in patients with benign prostate hyperplasia.
    Kurokawa S; Kamei J; Sakata K; Sugihara T; Fujisaki A; Ando S; Takayama T; Fujimura T
    Low Urin Tract Symptoms; 2022 Jul; 14(4):261-266. PubMed ID: 35170856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
    Lin VC; Liao CH; Kuo HC
    Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
    Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
    BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
    Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
    PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
    Kang D; Hu C; Fu Y; Wang D
    Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.